ACR Convergence 2020—On Nov. 8, 2020, Farshid Guilak, PhD, professor of orthopedic surgery at Washington University, St. Louis, Mo., and Shriners Hospitals for Children—St. Louis, gave the Oscar S. Gluck, MD, Memorial Lecture, describing his program’s multi-disciplinary approach to the treatment of arthritis.
Dr. Guilak began by describing osteoarthritis (OA) and rheumatoid arthritis (RA) as two different diseases sharing a common pathway of inflammation. His laboratory focuses on combining tissue engineering and stem cells to create a treatment for arthritis that can, at minimum, delay joint replacement.
Dr. Guilak
At its core, regenerative medicine uses stem cells to regenerates cells, tissues and organs to restore function. Stem cell therapy is the injection of stem cells into the body to treat disease, and tissue engineering combines cells, biomaterials and molecules to regenerate tissues and organs. Thus, it requires the creation of scaffolds of biocompatible materials that support tissue regeneration. These scaffolds can be made of soft gels with high-water content, which can be beneficial, but also result in a weak scaffold, making them unsuitable for withstanding joint loading.
Instead of gels, Dr. Guilak’s laboratory creates composite scaffolds of biocompatible fibers woven in three orthogonal directions (3D). The fibers can be woven tightly or loosely, and after the scaffold is created, they can be infiltrated with stem cells. These stem cells are then converted to cartilage or bone-producing cells. Over time, the biocompatible fibers are resorbed by the body. The result is a bioartificial cartilage with the properties of normal cartilage.
